New targeted therapies for non-small-cell lung cancer

Therapy

Volumn 6, Issue 3, 2009, Pages 335-350

  Metro, Giulio ^a   Cappuzzo, Federico ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Bevacizumab; Cetuximab; EGF receptor; Erlotinib; Gefitinib; Multitargeted agents; Non small cell lung cancer; Targeted therapies; Tyrosine kinase inhibitors; VEGF

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; AXITINIB; BEVACIZUMAB; BIBW 2992; CARBOPLATIN; CETUXIMAB; CISPLATIN; CP 751871; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PEMETREXED; PF 00299804; PLACEBO; PLATINUM; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; XL 184; XL 647;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; FATIGUE; GENE MUTATION; HUMAN; HYPERTENSION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PATIENT SELECTION; PHARMACOGENETICS; REVIEW; SOLID TUMOR; VOMITING;

EID: 69449099967     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.09.5     Document Type: Review

References (126)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
2. Shepherd FA, Rodrigues Pereira J et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
3. Sandler A, Gray R, Perry MC et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2450 (2006).
4. Pirker R, Szczesna A, von Pawel J et al.: FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Presented at: 44th American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
5. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311(7010), 899-909 (1995).
6. Cardenal F, Lopez-Cabrerizo M, Anton A et al.: Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 17(1), 12-18 (1999).
7. Crino L, Scagliotti GV, Ricci S et al.: Gemcitabine and cisplatin versus mitomycin, ifosfamidewild-type cisplatin in advanced non-small-cell lung cancer: a randomized Phase III study of the Italian Lung Cancer Project. J. Clin. Oncol. 17(11), 3522-3530 (1999).
8. Sandler A, Nemunaitis J, Dehnam C et al.: Phase III study of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 18(1), 122-130 (2000).
9. Giaccone G, Splinter TA, Debruyne C et al.: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J. Clin. Oncol. 16(6), 2133-2141 (1998).
10. Wozniak AJ, Crowley JJ, Balcerzak SP et al.: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J. Clin. Oncol. 16(7), 2459-2465 (1998).
11. Bonomi P, Kim K, Fairclough D et al.: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 18(3), 623-631 (2000).
12. Le Chevalier T, Brisgand D, Douillard JY et al.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J. Clin. Oncol. 12(2), 360-367 (1994).
13. Danson S, Middleton MR, O'Byrne KJ et al.: Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamidewild-type cisplatin or mitomycin, vinblastinewild-type cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer 98(3), 542-553 (2003).
14. Schiller JH, Harrington D, Belani CP et al.: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002).
15. Scagliotti GV, De Marinis F, Rinaldi M et al.: Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J. Clin. Oncol. 20(21), 4285-4292 (2002).
16. Smit EF, van Meerbeeck JP, Lianes P et al.: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J. Cln. Oncol. 21(21), 3909-3917 (2003).
17. Huang SM, Harari PM: Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs 17(3), 259-269 (1999).
18. Steiner P, Joynes C, Bassi R et al.: Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin. Cancer Res. 13(5), 1540-1551 (2007).
19. Raben D, Helfrich B, Chan DC et al.: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer Res. 11(2 Pt 1), 795-805 (2005).
20. Hanna N, Lilenbaum R, Ansari R et al.: Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J. Clin. Oncol. 24(33), 5253-5258 (2006).
21. Thienelt CD, Bunn PA Jr, Hanna N et al.: Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 23(34), 8786-8793 (2005).
22. Robert F, Blumenschein G, Herbst RS et al.: Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J. Clin. Oncol. 23(36), 9089-9096 (2005).
23. Borghaei H, Langer CJ, Millenson M et al.: Phase II study of paclitaxel, carboplatin wild-type cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J. Thorac. Oncol. 3(11), 1286-1292 (2008).
24. Belani CP, Schreeder MT, Steis RG et al.: Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter Phase 2 study. Cancer 113(9), 2512-2517 (2008).
25. Herbst RS, Chansky K, Kelly K et al.: A Phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342. Presented at: 43rd American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
26. Rosell R, Robinet G, Szczesna A et al.: Randomized Phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/ vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 19(2), 362-369 (2008).
27. Lynch TJ, Patel T, Dreisbach L et al.: Overall survival (os) results from the Phase III trial BMS 099: cetuximab + taxane/carboplatin as 1st-line treatment for advanced NSCLC. Presented at: Chicago Multidisciplinary Symposium in Thoracic Oncology. Chicago, IL, USA, 13-15 November 2008.
28. Mukohara T, Engelman JA, Hanna NH et al.: Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl Cancer Inst. 97(16), 1185-1194 (2005).
29. Cappuzzo F, Finocchiaro G, Rossi E et al.: EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann. Oncol. 19(4), 717-723 (2008).
30. Cappuzzo F, Varella-Garcia M, Finocchiaro G et al.: Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br. J. Cancer 99(1), 83-89 (2008).
31. Cappuzzo F, Marchetti A, Skokan M et al.: Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 27(10), 1667-1674 (2009).
32. Hirsch FR, Herbst RS, Olsen C et al.: Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J. Clin. Oncol. 26(20), 3351-3357 (2008).
33. Khambata-Ford A, Harbison CT, Hart LL et al.: K-Ras mutations (mt) and EGFR-related markers as potential predictors of cetuximab benefit in 1st line advanced NSCLC: results from the BMS099 study. Presented at: Chicago Multidisciplinary Symposium in Thoracic Oncology. Chicago, IL, USA, 13-15 November 2008.
34. Karapetis CS, Khambata-Ford S, Jonker DJ et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
35. Ranson M, Hammond LA, Ferry D et al.: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial. J. Clin. Oncol. 20(9), 2240-2250 (2002).
36. Nakagawa K, Tamura T, Negoro S et al.: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol. 14(6), 922-930 (2003).
37. Herbst RS, Maddox AM, Rothenberg ML et al.: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a Phase I trial. J. Clin. Oncol. 20(18), 3815-3825 (2002).
38. Baselga J, Rischin D, Ranson M et al.: Phase I safety, pharmacokinetic wild-type pharmacodynamic trial o ZD 1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20(21), 4292-4302 (2002).
39. Goss G, Hirte H, Miller Jr WH et al.: A phase I study of oral ZD1839 given daily in solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Invest. New Drugs 23(2), 147-155 (2005).
40. Kris MG, Natale RB, Herbst RS et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16), 2149-2158 (2003).
41. Perez-Soler R, Chachoua A, Hammond L et al.: Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 22(16), 3238-3247 (2004).
42. Tsao MS, Sakurada A, Cutz JC et al.: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 353(2), 133-144 (2005).
43. Thatcher N, Chang A, Parikh P et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527-1537 (2005).
44. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al.: Molecular predictors of outcome with gefitinib in a Phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24(31), 5034-5042 (2006).
45. Kim ES, Hirsh V, Mok T et al.: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet 372(9652), 1809-1818 (2008).
46. Giaccone G, Herbst RS, Manegold C et al.: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 1. J. Clin. Oncol. 22(5), 777-784 (2004).
47. Herbst RS, Giaccone G, Schiller JH et al.: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2. J. Clin. Oncol. 22(5), 785-794 (2004).
48. Herbst RS, Prager D, Hermann R et al.: TRIBUTE - A Phase III trial of erlotinib hydochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
49. Gatzemeier U, Pluzanska A, Szczesna A et al.: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small cell lung cancer: the tarceva lung cancer investigation trial. J. Clin. Oncol. 25(12), 1545-1552 (2007).
50. Eberhard DA, Johnson BE, Amler LC et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23(25), 5900-5909 (2005).
51. Hida T, Okamoto I, Kashii T et al.: Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): results of West Japan Thoracic Oncology Group trial (WJTOG). Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
52. Mok T, Wu YL, Thongprasert S et al.: Phase III, randomised, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) (IPASS). Presented at: European Society for Clinical Oncology Congress. Stockholm, Sweden, 12-16 September 2008.
53. Paez JG, Jänne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004).
54. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
55. Pao W, Miller V, Zakowski M et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101(36), 13306-13311 (2004).
56. Takano T, Ohe Y, Sakamoto H et al.: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23(28), 6829-6837 (2005).
57. Han SW, Kim TY, Hwang PG et al.: Predictive and prognostic impact of epidermal growth factor receptor mutation in non small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23(11), 2493-2501 (2005).
58. Kim KS, Jeong JY, Kim YC et al.: Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin. Cancer Res. 11(6), 2244-2251 (2005).
59. Cortes-Funes H, Gomez C, Rosell R et al.: Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small cell lung cancer patients. Ann. Oncol. 16(7), 1081-1086 (2005).
60. Buckingham LE, Coon JS, Morrison LE et al.: The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J. Thorac. Oncol. 2(5), 414-422 (2007).
61. Chou TY, Chiu CH, Li LH et al.: Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res. 11(10), 3750-3757 (2005).
62. Taron M, Ichinose Y, Rosell R et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin. Cancer Res. 11(16), 5878-5885 (2005).
63. Mu XL, Li LY, Zhang XT et al.: Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin. Cancer Res. 11(12), 4289-4294 (2005).
64. Zhang XT, Li LY, Mu XL et al.: The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann. Oncol. 16(8), 1334-1342 (2005).
65. Mitsudomi T, Kosaka T, Endoh H et al.: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment inpatients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. (11), 2513-2520 (2005).
66. Cappuzzo F, Ligorio C, Janne PA et al.: Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J. Clin. Oncol. 25(16), 2248-2255 (2007).
67. Yang CH, Yu CJ, Shih JY, et al.: Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J. Clin. Oncol. 26(16), 2745-2753 (2008).
68. Sequist LV, Martins RG, Spigel D et al.: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clin. Oncol. 26(15), 2442-2449 (2008).
69. Paz-Ares L, Sanchez JM, García-Velasco A et al.: A prospective Phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). Presented at: 42nd American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA, 2-6 June 2006.
70. Inoue A, Suzuki T, Fukuhara T et al.: Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 24(21), 3340-3346 (2006).
71. Asahina H, Yamazaki K, Kinoshita I et al.: A Phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br. J. Cancer 95(8), 998-1004 (2006).
72. Sutani A, Nagai Y, Udagawa K et al.: Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br. J. Cancer 95(11), 1483-1489 (2006).
73. Cappuzzo F, Hirsch FR, Rossi E et al.: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J. Natl Cancer Inst. 97(9), 643-655 (2005).
74. Goss G, Ferry, D, Laurie S et al.: Randomized, double-blind, multicenter, parallel-group, phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naive patients with advanced non small-cell lung cancer and poor performance status (INSTEP). Presented at: 12th World Conference on Lung Cancer. Seoul, Korea, 2-6 September 2007.
75. Marchetti A, Felicioni L, Buttitta F: Assessing EGFR mutations. N. Engl. J. Med. 354(5), 526-528 (2006).
76. Ferraran N: Molecular and biological properties of vascular endothelial growth factor. J. Mol. Med. 77(7), 527-543 (1999).
77. Kukk E, Lymboussaki A, Taira S et al.: VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development (1996) 122(12), 3829-3837 (1996).
78. Presta LG, Chen H, O'Connor SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20), 4593-4599 (1997).
79. Johnson DH, Fehrenbacher L, Novotny WF et al.: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184-2191 (2004).
80. Reck M, von Pawel J, Zatloukal P et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J. Clin. Oncol. 27(8), 1227-1234 (2009).
81. Vosseler S, Mirancea N, Bohlen P et al.: Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue wild-type reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res. 65(4), 1294-1305 (2005).
82. Hainsworth J, Herbst R: A Phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin®) in combination with erlotinib (Tarceva®) compared with erlotinib alone for treatment of advanced non-SMALL cell lung cancer after failure of standard first-line chemotherapy (BETA). Presented at: Chicago Multidisciplinary Symposium in Thoracic Oncology. Chicago, IL, USA, 13-15 November 2008.
83. Punt CJ, Tol J, Rodenburg CJ et al.: Randomized phase III study of capecitabine, oxaliplatin wild-type bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). Presented at: 44th American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
84. Riely GJ, Pao W, Pham D et al.: Clinical course of patients with non small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12(3 Pt 1), 839-844 (2006).
85. Pao W, Miller AV, Politi KA et al.: Aquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), E73 (2005).
86. Balak MN, Gong Y, Riely GJ et al.: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12(21), 6494-6501 (2006).
87. Kobayashi S, Boggon TJ, Dayaram T et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352(8), 786-792 (2005).
88. Engelman JA, Zejnullhau K, Mitsudomi T et al.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007).
89. Bean J, Brennan C, Shih JY et al.: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA 104(52), 20932-20937 (2007).
90. Cappuzzo F, Jänne PA, Skokan M et al.: MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol. 20(2), 298-304 (2009).
91. Riely GJ, Kris MG, Zhao B et al.: Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin. Cancer Res. 13(17), 5150-5155 (2007).
92. Ji H, Li D, Chen L et al.: The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9(6), 485-495 (2006).
93. Kwak EL, Sordella R, Bell DW et al.: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl Acad. Sci. USA 102(21), 7665-7677 (2005).
94. Li D, Ambrogio L, Shimamura T et al.: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34), 4702-4711 (2008).
95. Gonzales AJ, Hook KE, Althaus IW et al.: Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 7(7), 1880-1889 (2008).
96. Spicer J, Calvert H, Vidal L et al.: Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer with mutated EGFR. Presented at: 12th World Conference on Lung Cancer. Seoul, Korea, 2-6 September 2007.
97. Yang C, Shih J, Chao T et al.: Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial. Presented at: 44th American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
98. Janne PA, Schellens JH, Engelman JA et al.: Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC. Presented at: 44th American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
99. Gendreau SB, Ventura R, Keast P et al.: Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Clin. Cancer Res. 13(12), 3713-3723 (2007).
100. Rizvi NA, Kris MG, Miller VA et al.: Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2. Presented at: 44th American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
101. Miller VA, Wakelee HA, Lara PN et al.: Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: preliminary results of a phase II trial. Presented at: 44th American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
102. Besse B, Eaton KD, Soria JC et al.: Neratinib (HKI-272), an irreversible Pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a Phase 2 trial in patients with advanced non-small-cell lung cancer. Presented at: 20th EORTC-NCI-AACR Meeting. Geneva, Switzerland, 21-24 October 2008.
103. Toschi L, Jänne PA: Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin. Cancer Res. 14(19), 5941-5946 (2008).
104. Bianco R, Rosa R, Damiano V et al.: Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin. Cancer Res. 14(16), 5069-5080 (2008).
105. Wedge SR, Kendrew J, Hennequin LF et al.: AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65(10), 4389-4400 (2005).
106. Natale RB: Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. J. Thorac. Oncol. 3(6 Suppl. 2), S128-S130 (2008).
107. Heymach JV, Paz-Ares L, De Braud F et al.: Randomized Phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 26(33), 5407-5415 (2008).
108. Socinski MA, Novello S, Brahmer JR et al.: Multicenter, Phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J. Clin. Oncol. 26(4), 650-656 (2008).
109. Scagliotti G, Novello S, Brahmer J et al.: A Phase II study of continuous daily sunitinib dosing in patients with previously-treated advanced non-small cell lung cancer (NSCLC). Presented at: 12th World Conference on Lung Cancer. Seoul, Korea, 2-6 September 2007.
110. Adjei AA, Molina JR, Hillman SL et al.: A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: a North Central Cancer Treatment Group study. Presented at: 43rd American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1-6 June 2007.
111. Gatzemeier U, Blumenschein G, Fosella F et al.: Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. Presented at: 42nd American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA, 2-6 June 2006.
112. Schiller JH, Larson T, Ou I et al.: Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial. Presented at: 43rd American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1-6 June 2007.
113. Khandwala HM, McCutcheon IE, Flyvbjerg A et al.: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 21(3), 215-244 (2000).
114. Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16(1), 3-34 (1995).
115. LeRoith D, Werner H, Beitner-Johnson D et al.: Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr. Rev. 16(2), 143-163 (1995).
116. Jones HE, Goddard L, Gee JM et al.: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr. Relat. Cancer 11(4), 793-814 (2004).
117. Morgillo F, Kim WY, Kim ES et al.: Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin. Cancer Res. 13(9), 2795-2803 (2007).
118. Cappuzzo F, Toschi L, Tallini G et al.: Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol. 17(7), 1120-1127 (2006).
119. Karp DD, Paz-Ares LG, Blakely LJ et al.: Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). Presented at: 43rd American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1-6 June 2007.
120. Gualberto A, Melvin CL, Dean A et al.: Characterization of NSCLC patients responding to anti-IGF-IR therapy. Presented at: 44th American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
121. Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 103(2), 253-262 (2000).
122. Balsara BR, Pei J, Mitsuchi Y et al.: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25(11), 2053-2059 (2004).
123. Molina JR, Mandrekar S, Rowland K et al.: A Phase II NCCTG Window of Opportunity Front-line study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLC. Presented at: 12th World Conference on Lung Cancer. Seoul, Korea, 2-6 September 2007.
124. Papadimitrakopoulou V, Soria JC, Douillard JY et al.: A Phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I). Presented at: 43rd American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1-6 June 2007.
125. Kris MG, Riely GJ, Azzoli CG et al.: Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial. Presented at: 43rd American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1-6 June 2007.
126. Papadimitrakopoulou V, Blumenschein GR, Leighl NB et al.: A Phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results. Presented at: 44th American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.